Log in
menu
RESOURCES
Guides
API
FAQ
Recent Changes
Report Issue
ABOUT
About Wikirate
Community
Data
Impact
All Categories
--------------
Companies
Metrics
Sources
Topics
Data Sets
Projects
Research Groups
Company Groups
search
arrow_back_ios
Companies
Metrics
Sources
Topics
Data Sets
Projects
Research Groups
Company Groups
arrow_forward_ios
Karyopharm Therapeutics Inc
+
Answer
history
edit
build
2021
Interest Payable
Research
lock_open
23.9M
USD
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
2021
Liabilities
Research
lock_open
385M
USD
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
2021
Long-term Debt
Research
lock_open
169M
USD
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
2021
Net Income
Research
lock_open
-124M
USD
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
2021
Operating Expenses
Research
lock_open
308M
USD
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
2021
Operating Income (Loss)
Research
lock_open
-98.3M
USD
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
2021
Payments for Royalties
Research
lock_open
10.4M
USD
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
2021
Research and Development Expense
Research
lock_open
161M
USD
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
2021
Standard Industrial Classification Code
Research
lock_open
Pharmaceutical Preparations
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
2021
Standard Industrial Classification Division
Formula
calculator
Manufacturing
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
2020
Comprehensive Income Net of Tax
Research
lock_open
-196M
USD
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
2020
Net Income Attributable to the company
Research
lock_open
-196M
USD
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
2020
Assets
Research
lock_open
313M
USD
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
2020
Deferred Income Tax Expense Benefit
Research
lock_open
0
USD
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
2020
Deferred Revenue
Research
lock_open
297,000
USD
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
2020
Effective Income Tax Rate Continuing Operations
Research
lock_open
-0.002
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
2020
Income Loss From Continuing Operations Before Income Taxes Foreign
Research
lock_open
-37.1M
USD
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
2020
Income Tax Expense Benefit
Research
lock_open
309,000
USD
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
2020
Liabilities
Research
lock_open
263M
USD
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
2020
Net Income
Research
lock_open
-196M
USD
more_horiz
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
attribution
Attribute
edit
Edit
build
Advanced
«
1
2
3
4
...
8
»
21 - 40 of 148